Immix Biopharma Investor Presentation Deck
Select Leadership
Select
Leadership
Ilya Rachman, MD, PhD
Founder & Chief Executive Officer
Nexcella Executive Chairman
Physician/scientist, co-founded ImmixBio after serving as
a clinical investigator for GlaxoSmithKline registrational
clinical trials (TRELEGY ELLIPTAⓇ) and Eli Lilly post-
approval clinical trials
Cedars
Sinai
UCLA Health
UIC COLLEGE OF
AT CHICAGO MEDICINE
UNIVERSITY OF ILLINOIS
Nandan Oza, BS
Head of Chemistry,
Manufacturing and Control
Jazz Pharmaceuticals.
• >10 years at Goldman Sachs and other global banks
leading mergers & acquisitions, entrepreneur, published
research
• >20 years extensive CMC experience in organizations
ranging from start-ups to large pharmaceutical
companies
ZOSANO.
PHARMA
Gabriel Morris, BA
Chief Financial Officer
Nexcella President
COLUMBIA UNIVERSITY
IN THE CITY OF NEW YORK
TALON
PHARMACEUTICALS
Goldman
Sachs
Qi Wen, CFA, MBA
Vice President
-20
Corporate Strategy
Head of Business Development
CHICAGO BOOTH
The University of Chicagu Booth School of Business
• >10 years investment and equity research experience
including Bank of America and Jefferies
>20 years in clinical drug development, leading clinical trials
for pertuzumab (PERJETAⓇ) and leading the clinical filing
team for atezolizumab (TECENTRIQ®) at Roche
gsk
Roche
BANK OF AMERICA
●●●
IMMIX
S BIOPHARMA
Jefferies
Graham Ross, MBChB,
FFPM
Chief Medical Officer
AstraZeneca
50View entire presentation